All News

A non-bone-anchored male sling appears to resolve mild to moderate post-prostatectomy incontinence in up to 80% of patients and may also lead to significant improvement in erectile and sexual function.

A solitary positive apical margin following radical prostatectomy is associated with a higher biochemical recurrence rate than are negative surgical margins., but positive apical margins are associated with a lower recurrence rate than non-apical or multifocal positive margins are.

"We're just starting, but I'm not looking forward to it."

A study by psychologists and urologists has found that factors affecting erectile function after prostatectomy have much the same impact after other prostate cancer treatments.

Most women who undergo sacral neuromodulation for refractory overactive bladder report concomitant bowel symptoms when asked.

AUA has addressed a number of questions and controversies concerning small renal masses in a new clinical guideline reflecting current research. Steven C. Campbell, MD, PhD, guideline co-chair, discusses the rationale for the guideline and key recommendations.

Planned radical prostatectomy within 8 weeks of preoperative radiotherapy is well tolerated and may result in downstaging of the disease, according to results of a phase I study.

The superiority of nephron-sparing surgery over radical nephrectomy in preserving renal function extends to tumors larger than 4 cm.

Urologists are being urged to actively participate in health care reform because the result will have a major impact on how they conduct their practices and treat their patients for years to come.

360 Network

The controversial concept of medical home calls for a team led by a physician, usually a primary care physician, to be paid extra to handle personalized coordination of a patient's care across the health care system, including acting as liaison with other providers.

In select patients with renal cortical tumors up to 7 cm in size, partial nephrectomy appears to be a reasonable option that doesn't compromise overall or cancer-specific survival.

A standardized scoring system for grading the anatomy of renal masses enables meaningful comparisons of outcomes and provides a clinical tool for guiding tumor management decisions.

New bladder cancer data are food for thought, but are not conclusive proof that urologists are over-treating early-stage bladder cancer and running up costs.

With all of the negative sentiment surrounding the financial markets, is it appropriate to simply avoid them until things improve?

Aggressive treatment for early-stage bladder cancer does not appear to benefit patients with the disease and may even increase the likelihood for later intervention compared with less-intensive treatment.

Researchers at the University of California, San Francisco have developed a new surgical approach they call a "T-shunt" that appears to resolve ischemic priapism efficiently and effectively with minimal morbidity.

Waiting time to nephrectomy is not a predictor of the recurrence of renal cell carcinoma.

A significant number of patients undergoing open or robotic radical prostatectomy have unrealistic expectations about postoperative sexual function.

The substantial decrease in the use of LHRH agonists in the U.S. since 2004 may not be entirely explained by a recent reduction in physician reimbursement.

Urology Times has received two awards for cover design in recent national journalism competitions.

Mylan Pharmaceuticals Inc., Sun Pharmaceutical Industries, and Sandoz Inc. have received FDA approval for their generic formulations of bicalutamide tablets, 50 mg.

Micheal Chehval, MD, has been appointed chief of urology at Saint Louis University School of Medicine.

Through a new contractual relationship between Cook Medical and Premier Purchasing Partners, LP, more than 2,100 U.S. hospitals and 58,000 additional health care providers will have access to special pricing and terms of Cook?s Biodesign Advanced Tissue Repair products, designed for four types of soft tissue repair: continence restoration, fistula repair, vaginal erosion repair, and pelvic floor reconstruction.

American Medical Systems, Inc. has received FDA approval for the AMS 700 with Inhibizone as the only inflatable penile prosthesis with clinical evidence showing a significant reduction in the rate of revision surgery due to infection.

Treatment with sunitinib malate (Sutent) appears to prolong progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer patients with a poor prognosis, including the elderly and those whose cancer has spread to the brain, according to a study to be published in The Lancet Oncology.

Treatments for prostate cancer are among 100 health topics that should receive priority attention and funding from a new national research effort to identify which health care services are most effective.

John Wertman has been appointed government relations and advocacy manager, states and sections, for AUA?s expanded government relations program.

Prostate cancer patients who receive brachytherapy and remain free of disease for 5 years are unlikely to have a recurrence at 10 years, according a new study by researchers from Mount Sinai Medical Center, New York.

Patients with inherited forms of advanced prostate, breast, and ovarian cancers caused by mutations in the BRCA1 and BRCA2 genes experienced tumor shrinkage without major side effects when treated with the investigational drug olaparib (AZD-2281), a recently published phase I study showed.